Status:
COMPLETED
Alternate-Day Buprenorphine Administration. Phase VIII - 9
Lead Sponsor:
University of Vermont
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
25-48 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate open buprenorphine dosing with dose choice.
Eligibility Criteria
Please contact site for information.
Key Trial Info
Start Date :
August 1 1994
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000227
Start Date
August 1 1994
Last Update
May 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Treatment Research Center
Burlington, Vermont, United States, 05401